We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Maximum Tolerated Dose of CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

- Solid Tumors
- Completed

Study Title: To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Teva Identifier: C37440/1108

ClinicalTrials.gov Identifier: NCT01922752

Study Status: Completed

Trial Condition(s): Solid Tumors

Interventions: Drug: CEP-37440

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

ClinicalTrials.gov study records with inclusion and exclusion criteria

cancer icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 07/01/2013 - 12/01/2015

Phase: Phase 1

Study Type

Interventional